ArticleOdontology2026
Assessment of apoptosis and autophagy in oral squamous cell carcinoma cell line treated with salivary exosomes.
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma (OSCC) is a leading cause of cancer-related mortality worldwide. Salivary exosomes (sExosomes), a subtype of extracellular vesicles, have gained attention for their role in intercellular communication and their potential as non-invasive diagnostic and therapeutic tools. This study investigated the therapeutic effects of sExosomes on OSCC by examining cellular ultrastructure and assessing the expression of caspase-3 and the autophagy-related gene NKX2-3. Human OSCC cells (SCC-25) were cultivated in Dulbecco's Modified Eagle Medium (DMEM) containing 10% exosome-depleted fetal bovine serum (FBS) and 1% penicillin-streptomycin (PS). sExosomes were isolated from human saliva using differential ultracentrifugation and confirmed via transmission electron microscopy (TEM). The experiment included two groups: Group I (untreated OSCC cells) and Group II (OSCC cells treated with sExosomes for 14 days). Ultrastructural examination revealed abnormal mitotic figures, chromatin clumping, and enlarged mitochondria in Group I, whereas Group II showed features characteristic of apoptosis, including pyknotic nuclei, cytoplasmic vacuolization, and degenerated organelles. ELISA results indicated significantly higher caspase-3 levels in Group II (305.33) compared to Group I (91.03), suggesting enhanced apoptotic activity. Conversely, NKX2-3 expression was significantly lower in Group II (0.89) than in Group I (2.65), indicating suppression of autophagy-related signaling. Statistical analysis was conducted using an independent-samples t-test, with significance set at p < 0.05. These findings support the potential of sExosomes to modulate tumor behavior by promoting apoptosis and inhibiting autophagy in OSCC, underscoring their promise as novel therapeutic agents in future cancer treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.